Background
This study evaluated biomarker profiles associated with therapeutic response and prognosis in resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant camrelizumab plus chemotherapy.
Methods
In this single-arm phase II trial, pa…
Background
As a key downstream effector of the Hippo signaling pathway, Yes-associated protein (YAP) has emerged as a pivotal regulator of tumor immune evasion and resistance to immune checkpoint inhibitors (ICIs). However, the relationship between YA…
Background
CD70, overexpressed in multiple myeloma (MM), is a promising target for theranostics. This study developed a CD70-targeted theranostic pair: the immuno-positron emission tomography tracer [89Zr]Zr-DFO-ABDB6 and the therapeutic agent [177Lu]…
Background
The efficacy of chemo-immunotherapy in gastric cancer (GC) is limited by heterogeneous resistance and the lack of predictive biomarkers. However, the molecular mechanisms underlying concurrent intrinsic chemoresistance and extrinsic immunos…
Background
CD47 functions as a “don’t eat me” checkpoint, inhibiting macrophage-mediated phagocytosis in triple-negative breast cancer (TNBC). While anti-CD47 therapies can restore immune surveillance, their efficacy in TNBC is often limited by …
Background
The immunologically “cold” microenvironment of triple-negative breast cancer presents a major obstacle to treatment, conferring resistance to current immunotherapies. Targeting the stimulator of interferon genes (STING) pathway has emerged …
Background
The secretion of interferon- (IFN-) by activated immune cells is one of the hallmarks of response to cancer immunotherapy. Hence, detection of this cytokine via imaging can help determine an activated antitumor immune response. We have prev…
Background
Neoadjuvant chemoimmunotherapy (NACI) has shown promising results in treating esophageal squamous cell carcinoma (ESCC), yet the mechanisms driving its efficacy remain poorly defined, limiting further optimization of this regimen.
Methods
…
Background
Despite its viral etiology and immunogenic features, cervical cancer shows limited and often short-lived benefit from programmed cell death protein 1 blockade, currently the only approved immunotherapy for this disease. This limitation high…
Background
Immune checkpoint blockade (ICB) has revolutionized cancer therapy, yet resistance—both primary and acquired—remains a significant obstacle, affecting the majority of patients.
Methods
Here, we leverage a large-scale, real-worl…
